Crinetics outlines 2025 milestones: paltusotine PDUFA Sept 25, atumelnant Ph3 start H1 2025

Crinetics Pharmaceuticals, Inc.

Paltusotine NDA under FDA review; PDUFA target action date set for September 25, 2025.
Atumelnant Phase 3 initiation for adult CAH patients expected in H1 2025; pediatric CAH and Cushing's disease later-stage trials planned in 2025.
Four development candidates advancing toward IND-enabling studies for NETs, hyperparathyroidism, Graves' disease, thyroid eye disease, and ADPKD.
CEO Scott Struthers presenting at 43rd J.P. Morgan Healthcare Conference on January 14, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.